Glenn J. Bubley MD
Director, Genitourinary Medical Oncology
Beth Israel Deaconess Medical Center
Dr. Glenn Bubley has been involved in clinical/translational research in prostate cancer for more than 25 years as well as had a role in the Dana-Farber / Harvard Cancer Center (DF/HCC) Prostate Cancer Spore involving administrative and scientific input on several projects and cores during this time. He is currently a PI of trials that involve new agents for prostate cancer; as well as an investigator in studies involving prostate cancer prevention efforts and active surveillance studies. Dr. Bubley has had the opportunity to work in a translational capacity with investigators like Xin Yuan, Steve Balk, Huihui Ye and Max Loda, specifically involving investigations on prostate cancer tumor samples. He is also involved in the DF/HCC as the program leader for GU-Oncology at Beth Israel Deaconess Medical Center, a position he has held for more than 15 years. Dr. Bubley has also coordinated a prostate cancer tumor board for more than 15 years as well as been the PI and Site Director of the Eastern Cooperative Oncology Group (ECOG) at Beth Israel Deaconess Medical Center overseeing all ECOG activity at the institution. Dr. Bubley also continues his role as physician advisor to the Boston Prostate Cancer Support Group.